or Try an Advanced Search...

    Technical Analysis for APGE - Apogee Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 53.23 2.46% 1.28
    APGE closed up 2.46 percent on Friday, October 25, 2024, on 53 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical APGE trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish 2.46%
    Lower Bollinger Band Walk Weakness 2.46%
    BB Squeeze Ended Range Expansion 2.46%
    Lower Bollinger Band Touch Weakness 2.46%
    Oversold Stochastic Weakness 2.46%
    MACD Bearish Centerline Cross Bearish 3.50%
    Older End-of-Day Signals for APGE ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 10 DMA 2 days ago
    10 DMA Resistance 2 days ago
    Rose Above Previous Day's High 2 days ago
    Up 3% 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    APGE Chart by TradingView
    Basic chart:

    Profile

    Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd

    Is APGE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 24 Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
    Oct 16 Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
    Oct 7 Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now
    Oct 4 Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc
    Sep 12 Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
    Sep 9 Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
    Aug 24 Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
    Aug 19 Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
    Aug 12 Apogee Therapeutics files potential mixed shelf
    Aug 12 Apogee Therapeutics reports Q2 results
    See more APGE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 72.29
    52 Week Low 14.22
    Average Volume 387,815
    200-Day Moving Average 48.12
    50-Day Moving Average 52.58
    20-Day Moving Average 54.93
    10-Day Moving Average 53.86
    Average True Range 2.64
    RSI (14) 48.19
    ADX 20.46
    +DI 20.26
    -DI 20.41
    Chandelier Exit (Long, 3 ATRs) 52.17
    Chandelier Exit (Short, 3 ATRs) 58.84
    Upper Bollinger Bands 58.89
    Lower Bollinger Band 50.97
    Percent B (%b) 0.28
    BandWidth 14.42
    MACD Line -0.21
    MACD Signal Line 0.43
    MACD Histogram -0.6392
    Fundamentals Value
    Market Cap 2.56 Billion
    Num Shares 48 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 56.22
    Resistance 3 (R3) 56.29 55.36 55.72
    Resistance 2 (R2) 55.36 54.60 55.33 55.55
    Resistance 1 (R1) 54.30 54.13 54.83 54.23 55.39
    Pivot Point 53.37 53.37 53.64 53.34 53.37
    Support 1 (S1) 52.31 52.61 52.84 52.24 51.07
    Support 2 (S2) 51.38 52.14 51.35 50.91
    Support 3 (S3) 50.32 51.38 50.74
    Support 4 (S4) 50.25